157 related articles for article (PubMed ID: 38105006)
1. Effect of Tegafur-Uracil in Resected Stage IB Lung Adenocarcinoma According to Presence or Absence of Epidermal Growth Factor Receptor Gene Mutation: A Retrospective Cohort Study.
Aoki M; Miyata R; Kamimura G; Harada Takeda A; Suetsugu T; Mizuno K; Ueda K
Ann Thorac Cardiovasc Surg; 2024 Jan; 30(1):. PubMed ID: 38105006
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic characteristics and prognostic impact of atypical EGFR mutations in completely resected lung adenocarcinoma.
She Y; Li S; Deng J; Ren Y; Zhao M; Zhong Y; He Y; Chen Q; Zhao D; Zhu Y; Hou L; Wu C; Xie D; Chen C
Eur J Cancer; 2022 Dec; 177():53-62. PubMed ID: 36323053
[TBL] [Abstract][Full Text] [Related]
3. Advantage of post-operative oral administration of UFT (tegafur and uracil) for completely resected p-stage I-IIIa non-small cell lung cancer (NSCLC).
Tanaka F; Miyahara R; Ohtake Y; Yanagihara K; Fukuse T; Hitomi S; Wada H
Eur J Cardiothorac Surg; 1998 Sep; 14(3):256-62; discussion 263-4. PubMed ID: 9761434
[TBL] [Abstract][Full Text] [Related]
4. Alpha-actinin-4 (ACTN4) gene amplification is a predictive biomarker for adjuvant chemotherapy with tegafur/uracil in stage I lung adenocarcinomas.
Noro R; Honda K; Nagashima K; Motoi N; Kunugi S; Matsubayashi J; Takeuchi S; Shiraishi H; Okano T; Kashiro A; Meng X; Yoshida Y; Watanabe S; Usuda J; Inoue T; Wilber H; Ikeda N; Seike M; Gemma A; Kubota K
Cancer Sci; 2022 Mar; 113(3):1002-1009. PubMed ID: 34845792
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
Suehisa H; Toyooka S; Hotta K; Uchida A; Soh J; Fujiwara Y; Matsuo K; Ouchida M; Takata M; Kiura K; Date H
J Clin Oncol; 2007 Sep; 25(25):3952-7. PubMed ID: 17761979
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
7. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
Lee KH; Chung JH; Cho S; Lee JS; Kim H
Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
[TBL] [Abstract][Full Text] [Related]
8. Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
Ito M; Miyata Y; Tsutani Y; Ito H; Nakayama H; Imai K; Ikeda N; Okada M
Lung Cancer; 2020 Mar; 141():107-113. PubMed ID: 32035371
[TBL] [Abstract][Full Text] [Related]
9. Prognostic influence of epidermal growth factor receptor mutation and radiological ground glass appearance in patients with early-stage lung adenocarcinoma.
Aokage K; Miyoshi T; Wakabayashi M; Ikeno T; Suzuki J; Tane K; Samejima J; Tsuboi M
Lung Cancer; 2021 Oct; 160():8-16. PubMed ID: 34365179
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
11. Combination of epidermal growth factor receptor mutation and the presence of high-grade patterns is associated with recurrence in resected stage I lung adenocarcinoma.
Kondo Y; Ichinose J; Ninomiya H; Hashimoto K; Matsuura Y; Nakao M; Ishikawa Y; Okumura S; Satoh Y; Mun M
Interact Cardiovasc Thorac Surg; 2022 Jul; 35(2):. PubMed ID: 35266536
[TBL] [Abstract][Full Text] [Related]
12. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma.
Tsutani Y; Ito M; Shimada Y; Ito H; Ikeda N; Nakayama H; Okada M
J Thorac Cardiovasc Surg; 2022 Nov; 164(5):1306-1315.e4. PubMed ID: 35181001
[TBL] [Abstract][Full Text] [Related]
13. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological and molecular characteristics of resected EGFR-mutant lung adenocarcinoma.
Zhou W; Liu Z; Wang Y; Zhang Y; Qian F; Lu J; Wang H; Gu P; Hu M; Chen Y; Yang Z; Zhao R; Lou Y; Han B; Zhang W
Cancer Med; 2022 Mar; 11(5):1299-1309. PubMed ID: 35023616
[TBL] [Abstract][Full Text] [Related]
15. Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Yamaguchi M; Tada H; Mitsudomi T; Seto T; Yokoi K; Katakami N; Nakagawa K; Oda M; Ohta M; Sawa T; Yamashita M; Iked N; Saka H; Higashiyama M; Nomori H; Semba H; Negoro S; Chiba Y; Shimokawa M; Fukuoka M; Nakanishi Y;
Int J Clin Oncol; 2021 Dec; 26(12):2216-2223. PubMed ID: 34463869
[TBL] [Abstract][Full Text] [Related]
16. Oral uracil-tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early-stage non-small cell lung cancer patients.
Liang SK; Wu CW; Chang CI; Keng LT; Lee MR; Wang JY; Ko JC; Liao WY; Chen KY; Ho CC; Shih JY; Yu CJ
Cancer Med; 2023 Sep; 12(17):17993-18004. PubMed ID: 37559409
[TBL] [Abstract][Full Text] [Related]
17. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
18. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K-ras mutation.
Kaseda K; Asakura K; Kazama A; Ozawa Y
Thorac Cancer; 2017 May; 8(3):229-237. PubMed ID: 28322512
[TBL] [Abstract][Full Text] [Related]
20. The radiological characteristics, tertiary lymphoid structures, and survival status associated with EGFR mutation in patients with subsolid nodules like stage I-II LUAD.
Xie M; Gao J; Ma X; Song J; Wu C; Zhou Y; Jiang T; Liang Y; Yang C; Bao X; Zhang X; Yao J; Jing Y; Wu J; Wang J; Xue X
BMC Cancer; 2024 Mar; 24(1):372. PubMed ID: 38528507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
